EGFR: A prognostic and/or a predictive marker?

Journal of Thoracic Oncology

Volumn 1, Issue 5, 2006, Pages 395-397

  Hirsch, Fred R ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; MONOCLONAL ANTIBODY; PLACEBO; TRASTUZUMAB; TUMOR MARKER;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DINUCLEOTIDE REPEAT; DISEASE MARKER; DNA POLYMORPHISM; DNA SEQUENCE; EDITORIAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FREQUENCY; GENE NUMBER; GENETIC TRANSCRIPTION; HUMAN; IMMUNOHISTOCHEMISTRY; INTRON; LUNG NON SMALL CELL CANCER; MOLECULAR CLONING; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; DRUG ANTAGONISM; GENETIC POLYMORPHISM; GENETICS; LUNG TUMOR; MORTALITY; NOTE;

CARCINOMA, NON-SMALL-CELL LUNG; DINUCLEOTIDE REPEATS; HUMANS; LUNG NEOPLASMS; POLYMORPHISM, GENETIC; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 33847016236     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01243894-200606000-00001     Document Type: Editorial

References (28)

1. Hirsch FR, Scagliotti GV, Langer CJ, et al. Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. Lung Cancer 2003;41:S29-S42.
2. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. JAMA 2003;290:2149-2158.
3. Perez-Soler R, Chachoua A, Hammond LA, et al. determinants of tumor response and survival with erlotinib in patients with non-small cell lung cancer. J Clin Oncol. 2004;22:3238-3247.
4. Cunningham D, Humblet Y, Siena S. et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345.
5. Bonner JA, Harari PM, Giralt J. et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-578.
6. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2006;353:123-132.
7. Tsao M-S, Sakurada A, Cutz J-C, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 2006;353:133-144.
8. Hirsch FR, Varella-Garcia M, Bunn PA, et al. Molecular analysis of EGFR gene copy number, EGFR expression and Akt activation status in advanced non-small cell lung cancer treated with gefitinib or placebo (ISEL trial) [Abstract A268]. Clin Cancer Res 2006;11(24 suppl):9031s.
9. Hirsch FR, Varella-Garcia M, McCoy J, et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchoalveolar carcinoma subtypes: a Southwest Oncology Group Study . J Clin Oncol 2006;23:6838-6845.
10. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer. J Natl Cancer Inst 2006;97:643-655.
11. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlining responsiveness of nonsmall cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
12. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
13. Maekawa T, Imamoto F, Merlino GT, et al. Cooperative function of two separate enhancers of the human epidermal growth factor receptor proto-oncogene. J Biol Chem 1989;264:5488-5494.
14. Haley JD, Waterfield MD. Contributory effects of de novo transcription and premature transcript termination in the regulation of human epidermal growth factor receptor proto-oncogene RNA synthesis. J Biol Chem 1991;266:1746-1753.
15. Gebhardt F, Zanker KS, Brandt B. Modulation of epidermal growth factor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem 1999;274:13176-13180.
16. Etienne-Grimaldi MC, Pereira S, Magne N, et al. Analysis of the dinucleotide repeat polymorphism in the epidermal growth factor receptor (EGFR) gene in head and neck cancer patients Ann Oncol 2006;16:934-941.
17. Dubey S, Stephenson P, Levy DE, et al. EGFR dinucleotide repeat polymorphism as a prognostic indicator in non-small cell lung cancer. J Thorac Oncol 2006.
18. Keller SM, Adak S, Wagner H, et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small cell lung cancer. N Engl J Med 2000;343:1217-1222.
19. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: A phase III trial of erlotinib HCI (OSI -774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small cell lung cancer [Abstract 7011]. J Clin Oncol 2004;22:617.
20. Eberhardt DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2006;23:5900-5909.
21. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2006;97:339-346.
22. Riely GJ, Pao W, Pham D, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or elotinib. Clin Cancer Res 2006;12:839-844.
23. Hirsch FR, Franklin WA, McCoy J, et al. Predicting clinical benefit from EGFR TKIs: not all EGFR mutations are equal! [Abstract 7072]. Proc Am Soc Clin Oncol 2006.
24. Hirsch FR, Varella-Garcia M, Bunn JrPA et al. Epidermal growth factor receptor in non-small cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003;21:3798-3807.
25. Dziadziuszko R, Holm B, Skov BG, et al. Prognostic significance of EGFR FISH and EGFR IHC in non-small cell lung cancer patients treated with chemotherapy alone [Abstract 7193]. Proc Am Soc Clin Oncol 2006.
26. Meert AP, Martin B, Delmotte P. et al. The role of EGFR expression on patient survival in lung cancer: a systemic review with meta-analysis. Eur Respir J 2002;20:975-981.
27. Nakamura H, Kawasaki N, Taguchi M, Kabasawa K, et al. Survival impact of epidermal growth factor receptor overexpression in patients with nonsmall cell lung cancer: a meta-analysis. Thorax 2006;61:140-145.
28. Slamon DJ, Clarke GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 1987;235:177-182.